Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,717 signal articles · 235 in last 24h · 134,347 total before filter · latest 51m ago
235last 24h
1108last 7d
178● bullish (7d)
132● bearish (7d)
209publishers
AllMacro294Earnings371M&A75Regulatory27Product10Analyst15
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearishshow all (incl. clickbait)
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Reuters50d agobearish
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.

UnitedHealth Group (UNH) Faces Wider DOJ Antitrust Probe As Claritev Review Expands
Simply Wall St.51d agobearish
UnitedHealth Group (UNH) Faces Wider DOJ Antitrust Probe As Claritev Review Expands

The U.S. Department of Justice has expanded an antitrust investigation to include UnitedHealth Group's Claritev unit. The Claritev review is part of broader DOJ scrutiny of healthcare industry practices and market competition. This development adds a fresh layer of regulatory attention for UnitedHealth Group (NYSE:UNH) beyond routine oversight. UnitedHealth Group, one of the largest managed care and healthcare services companies in the U.S., spans insurance, care delivery, and data-driven...

Meta layoffs take disturbing turn in new lawsuit
TheStreet51d agobearish
Meta layoffs take disturbing turn in new lawsuit

There’s no sugarcoating it; getting laid off is awful. But if you've been following the news, it feels like tech workers are being laid off left and right. Here’s what one Reddit user, who was recently laid off from an account executive role at a tech company, had to say on the r/Layoffs subreddit: ...

JD.com (JD) Faces 618 False Advertising Probe As Investor Lawsuit Risk Builds
Simply Wall St.55d agobearish
JD.com (JD) Faces 618 False Advertising Probe As Investor Lawsuit Risk Builds

Chinese regulators have summoned JD.com over alleged false advertising during the recent 618 shopping festival. The scrutiny centers on how promotional offers and discounts were presented during one of China's key mid year sales events. Law firm Pomerantz LLP has launched a securities fraud investigation linked to this regulatory action on behalf of JD.com investors. JD.com, listed on the NasdaqGS under the ticker NasdaqGS:JD, now sits in the spotlight as regulators and investors assess the...

Meta business model in trouble from $1.4 trillion lawsuit
TheStreet56d agobearish
Meta business model in trouble from $1.4 trillion lawsuit

If you have ever caught yourself doom scrolling on Instagram or Facebook for hours on end and felt bad, don't; the technology is working exactly how it was intended to. Everything from the length and style of the Reels to the algorithms' encyclopedic knowledge of your likes and dislikes is designed ...

Amgen (AMGN) Recalls Put Its Valuation Story Back In Focus
Simply Wall St.58d agobearish
Amgen (AMGN) Recalls Put Its Valuation Story Back In Focus

Amgen (AMGN) has moved into focus after initiating voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations, prompting investors to reassess drug quality and compliance risks. See our latest analysis for Amgen. Against this recall backdrop, Amgen’s recent momentum has stayed intact, with a 30 day share price return of 5.30% and a year to date share price return of 12.35%. The 1 year total shareholder return of 27.66% and 3 year...

Eli Lilly price target boost, Vertex-Crinetics deal, Meta's new social media lawsuit
Yahoo Finance Video58d agobearishVIDEO
Eli Lilly price target boost, Vertex-Crinetics deal, Meta's new social media lawsuit

Market Domination Host Josh Lipton tracks several of the day's top trending stock tickers, including JPMorgan analysts raising their price target on Eli Lilly (LLY) stock, Vertex Pharmaceuticals' (VRTX) acquisition of Crinetics (CRNX), and the possible $1.4 trillion lawsuit that multiple states are now suing Meta Platforms (META) for.